

Product Name	: TG-101348
Synonyms	: Fedratinib; SAR 302503; TG101348; TG 101348
Cat No.	: M16699
CAS Number	: 936091-26-8
Molecular Formula	: C ₂₇ H ₃₆ N ₆ O ₃ S
Formula Weight	: 524.68
Chemical Name	: Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-
Description	: TG-101348 (Fedratinib, SAR302503) is a potent, selective JAK2 inhibitor with IC ₅₀ of 3 nM for both wt JAK2 and JAK2 V617F; also inhibits FLT3 (IC ₅₀ =15 nM) and RET (IC ₅₀ =48 nM) kinases, weakly inhibits JAK3 (IC ₅₀ =168 nM), >35-fold selectivity over JAK1/3 and Tyk2; shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation; also potently inhibits BRD4 with K _d of 168 nM. Bone Cancer Phase 3 Clinical
Pathway	: Angiogenesis
Target	: JAK
Receptor	: FLT3; JAK2; JAK2(V617F); RET
Solubility	: DMSO: ≥ 42 mg/mL
SMILES	: <chem>O=S(=O)(NC(C)C)C1=CC=C(NC2=NC(NC3=CC=C(C(=O)OCCN4CCCC4)C=C3)N=C2C)=C1(NC(C)C)C=O</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Pardanani A, et al. Leukemia. 2007 Aug;21(8):1658-68. | 2. Ciceri P, et al. Nat Chem Biol. 2014 Apr;10(4):305-12. | 3. Wernig G, et al. Cancer Cell. 2008 Apr;13(4):311-20. | 4. Geron I, et al. Cancer Cell. 2008 Apr;13(4):321-30.